Literature DB >> 2108040

Congestive heart failure: involvement of perivascular peptides reflecting activity in sympathetic, parasympathetic and afferent fibres.

L Edvinsson1, R Ekman, P Hedner, S Valdemarsson.   

Abstract

In controls and in patients suffering from congestive heart failure (CHF) the circulating levels of catecholamines, neuropeptide Y-like immunoreactivity (NPY-LI), vasoactive intestinal peptide-LI (VIP-LI), substance P-LI (SP-LI) and calcitonin generated peptide-LI (CGRP-LI) markers of sympathetic, parasympathetic and sensory nervous systems, respectively, have been examined. There was a significant rise in the levels of noradrenaline, NPY-LI and SP-LI already in moderate CHF (New York Heart Association Stage I and II). In patients with severe CHF (NYHA Stage III and IV) the circulating levels of noradrenaline, adrenaline, NPY-LI and SP-LI were significantly increased. CGRP-LI was not altered, despite the fact that this peptide co-exists in many tissues with SP. There was no change in VIP-LI. The pathophysiological significance of this pattern of reaction of circulating catecholamines and neuropeptides is unclear; however, the rise in SP-LI may be a reaction to counterbalance the vasoconstrictive effects of the activation of the sympatho-adrenal system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2108040     DOI: 10.1111/j.1365-2362.1990.tb01796.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Role of substance P in viral myocarditis in mice.

Authors:  Yong Wang; Miho Shimada; Yawei Xu; Dayi Hu; Ryosuke Nishio; Akira Matsumori
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

2.  Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor.

Authors:  Andrew P Davie; John J V McMurray
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 3.  Neuroendocrine changes in chronic cardiac failure.

Authors:  D P Nicholls; G N Onuoha; G McDowell; J S Elborn; M S Riley; A M Nugent; I C Steele; C Shaw; K D Buchanan
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

4.  Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers.

Authors:  T Hedner; B Edgar; L Edvinsson; J Hedner; B Persson; A Pettersson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Plasma exudation in conscious dogs with experimental heart failure.

Authors:  I Rubinstein; G Müns; I H Zucker
Journal:  Basic Res Cardiol       Date:  1994 Sep-Oct       Impact factor: 17.165

6.  Neprilysin inhibition does not alter dynamic of proenkephalin-A 119-159 and pro-substance P in heart failure.

Authors:  Henrike Arfsten; Georg Goliasch; Philipp E Bartko; Suriya Prausmüller; Georg Spinka; Anna Cho; Johannes Novak; Julia Mascherbauer; Helmuth Haslacher; Guido Strunk; Martin Hülsmann; Noemi Pavo
Journal:  ESC Heart Fail       Date:  2021-03-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.